Jocelyn Chapman, MD

Jocelyn S. Chapman, MD

Berson Family Endowed Chair in Gynecologic Cancer, UCSF

Assistant Professor, Division of Gynecologic Oncology, Department of Obstetrics, Gynecology & Reproductive Sciences, UCSF

Cancer Center Program Membership

Molecular Oncology

Phone: (415) 885-3626

Box 1702, UCSF
San Francisco, CA 94143

Physician Biography

UCSF Profiles

Research Summary

Next-generation sequencing technologies developed in the last ten years have dramatically widened our view into the many kinds of events that are driving tumor biology. Gene fusions, copy number alterations, mutations, epigenetic changes, stromal microenvironment, immunogenicity and transcript level alterations can all be ascertained via the knife of DNA and RNA sequencing. Statistical methods, factor analysis, insights from evolutionary biology and immunology as well as an understanding of mutation processes at work in tumors can help us distill out the important driver events from the background of non-functional passenger mutations, and give us useful insights into the multiple systemic processes driving tumor progression.

I am specifically interested in using these integrated approaches to help understand and improve treatments for gynecologic cancers. However, the "organ of origin" approach has narrowed our view and exploring carcinogenesis pan-cancer will allow for novel insights into uncommon or difficult to treat gynecologic cancers. To this end, I collaborate with clinicians and scientists across oncology with a goal to further a model of cancer medicine in which genetic data is incorporated.

Education

Carnegie Mellon University, Pittsburgh, PA, B.F.A., 1996-1999, Classical piano
Columbia University, New York, NY, Post-bac, 2002-2003, Pre-medical sciences
Boston University School of Medicine, Boston, MA, M.D., 2004-2008, Medicine
University of California San Francisco, Resident, 2008-2012, Obstetrics, Gynecology & Reproductive Sciences
Stanford University and UCSF, Fellow, 2012-2015, Gynecologic Oncology

Honors & Awards

  • 2009
    Outstanding Resident Award in Medical Student Teaching
  • 2010
    Alpha Omega Alpha
  • 2011
    Resident Scholar - Association of Professors of Gynecology and Obstetrics
  • 2013 & 2014
    Outstanding Fellow Award in Medical Student Teaching
  • 2015
    Leo Lagasse Award for best fellow presentation on clinical research at the 2015 Western Association of Gynecologic Oncologists Annual Meeting

Selected Publications

  1. Zhu X, Alvarez EA, Umetsu SE, Chapman JS, Chen LM, Ueda S, Henderson S, Nguyen P, Calabrese S, Russell J, Aguilar J, Smith SA, Shah N, Feeney L, Van Ziffle J, Turski ML, Ko AH, Munster PN, Ashworth A, Collisson EA, Aggarwal RR. Efficacy of the ATR Inhibitor Ceralasertib in Patients with ARID1A-Deficient Gynecologic and Other Solid Tumor Malignancies. Clin Cancer Res. 2026 May 01; 32(9):1632-1640. View on PubMed
  2. Georgakopoulos-Soares I, Yizhar-Barnea O, Mouratidis I, Chan CSY, Patsakis M, Nayak A, Bradley R, Mahajan M, Sims J, Cintron DL, Easterlin R, Kim JS, Chen E, Pineda G, Parada GE, Witte JS, Maher CA, Feng F, Vathiotis I, Syrigos N, Panagiotou E, Charpidou A, Syrigos K, Chapman J, Kvale M, Hemberg M, Ahituv N. Leveraging sequences missing from the human genome to diagnose cancer. Commun Med (Lond). 2025 Aug 21; 5(1):363. View on PubMed
  3. Liu T, Zhang M, Farsh T, Li H, Kishishita A, Barpanda A, Leung SG, Zhu J, Jung H, Hua JT, Zhu X, Kim AB, Goo YA, Son M, Kim J, Subramanian A, Sjöström M, Fuh KC, Chapman JS, Carnevale J, Gilbert LA, Lakkaraju A, Bruno PM, Quigley D, Wiita AP, Feng FY, DeSelm CJ. Exploitable mechanisms of antibody and CAR mediated macrophage cytotoxicity. Nat Commun. 2025 Jul 01; 16(1):5616. View on PubMed
  4. Liang J, Mvemba A, Swanson M, Hsu IJ, Alvarez E, Chapman J, Fuh K, Chen LM, Cham S. Delay to timely treatment in locally advanced cervical cancer: insurance inequities in access to gynecologic oncology. Am J Obstet Gynecol. 2025 Sep; 233(3):186.e1-186.e9. View on PubMed
  5. Zhou Y, Chen X, Chapman JS, Barrett MT. Single nucleus DNA sequencing of flow sorted archived frozen and formalin fixed paraffin embedded solid tumors. BMC Genomics. 2024 Oct 08; 25(1):943. View on PubMed
  6. Chapman JS, Cassidy AG. Minimizing Morbidity in Placenta Accreta Spectrum: A Balance of Risks. Obstet Gynecol. 2024 09 01; 144(3):312-313. View on PubMed
  7. Guerra RA, Kaplan C, Borno H, Boscardin J, Alvarez EA, Lazar A, Chapman J, Swanson M, Ueda S, Chen LM. The role of race/ethnicity and age in clinical trial knowledge among patients with gynecologic malignancy. Gynecol Oncol. 2024 11; 190:84-89. View on PubMed
  8. Tsang ES, Dhawan MS, Pacaud R, Thomas S, Grabowsky J, Wilch L, Karipineni S, Kelley RK, Ko AH, Collisson E, Chapman JS, Ueda S, Bergsland EK, Munster P. Synthetic Lethality Beyond BRCA: A Phase I Study of Rucaparib and Irinotecan in Metastatic Solid Tumors With Homologous Recombination-Deficiency Mutations Beyond BRCA1/2. JCO Precis Oncol. 2024 06; 8:e2300494. View on PubMed
  9. Kay AH, Levy R, Hills N, Jang A, Mcgough-Maduena A, Dematteo N, Mark M, Ueda S, Chen LM, Chapman JS. Evidence-based prescribing of opioids after laparotomy: A quality-improvement initiative in gynecologic oncology. Gynecol Oncol Rep. 2024 Jun; 53:101396. View on PubMed
  10. Levy RA, Kay AH, Hills N, Chen LM, Chapman JS. Exploring the relationship between language, postoperative pain, and opioid use. AJOG Glob Rep. 2024 May; 4(2):100342. View on PubMed
  11. Levy RA, Diala PC, Rothschild HT, Correa J, Lehrman E, Markley JC, Poder L, Rabban J, Chen LM, Gras J, Sobhani NC, Cassidy AG, Chapman JS. Roadmap to safety: a single center study of evidence-informed approach to placenta accreta spectrum. Front Surg. 2024; 11:1347549. View on PubMed
  12. Kay AH, Othieno A, Boscardin J, Chen LL, Alvarez EA, Swanson M, Ueda S, Chen LM, Chapman JS. The past, present, and future of opioid prescribing: Perioperative opioid use in gynecologic oncology patients after laparotomy at a single institution from 2012 to 2021. Gynecol Oncol Rep. 2023 Apr; 46:101172. View on PubMed
  13. Hou JY, Chapman JS, Kalashnikova E, Pierson W, Smith-McCune K, Pineda G, Vattakalam RM, Ross A, Mills M, Suarez CJ, Davis T, Edwards R, Boisen M, Sawyer S, Wu HT, Dashner S, Aushev VN, George GV, Malhotra M, Zimmermann B, Sethi H, ElNaggar AC, Aleshin A, Ford JM. Circulating tumor DNA monitoring for early recurrence detection in epithelial ovarian cancer. Gynecol Oncol. 2022 11; 167(2):334-341. View on PubMed
  14. Avanzino BC, Prabhakar K, Dalvi P, Hartstein S, Kehm H, Balasubramani A, Boudreau AA, Buelow B, Chang K, Davison LM, Iyer S, Kalwit V, Lewis Wilson K, Malik-Chaudhry HK, Pierson W, Pineda G, Rangaswamy US, Saiganesh S, Schellenberger U, Ugamraj HS, Yabut RD, Buelow R, Chapman J, Trinklein ND, Harris KE. A T-cell engaging bispecific antibody with a tumor-selective bivalent folate receptor alpha binding arm for the treatment of ovarian cancer. Oncoimmunology. 2022; 11(1):2113697. View on PubMed
  15. Guix I, Liu Q, Pujana MA, Ha P, Piulats J, Linares I, Guedea F, Mao JH, Lazar A, Chapman J, Yom SS, Ashworth A, Barcellos-Hoff MH. Validation of Anticorrelated TGFβ Signaling and Alternative End-Joining DNA Repair Signatures that Predict Response to Genotoxic Cancer Therapy. Clin Cancer Res. 2022 04 01; 28(7):1372-1382. View on PubMed
  16. Combes AJ, Samad B, Tsui J, Chew NW, Yan P, Reeder GC, Kushnoor D, Shen A, Davidson B, Barczak AJ, Adkisson M, Edwards A, Naser M, Barry KC, Courau T, Hammoudi T, Argüello RJ, Rao AA, Olshen AB, Immunoprofiler Consortium, Cai C, Zhan J, Davis KC, Kelley RK, Chapman JS, Atreya CE, Patel A, Daud AI, Ha P, Diaz AA, Kratz JR, Collisson EA, Fragiadakis GK, Erle DJ, Boissonnas A, Asthana S, Chan V, Krummel MF. Discovering dominant tumor immune archetypes in a pan-cancer census. Cell. 2022 01 06; 185(1):184-203.e19. View on PubMed
  17. Korenaga TK, Yoshida EJ, Pierson W, Chang J, Ziogas A, Swanson ML, Chapman JS, Sinha S, Chen LM. Better late than never: Brachytherapy is more important than timing in treatment of locally advanced cervical cancer. Gynecol Oncol. 2022 02; 164(2):348-356. View on PubMed
  18. McNamara B, Guerra R, Qin J, Craig AD, Chen LM, Varma MG, Chapman JS. Survival impact of bowel resection at the time of interval cytoreductive surgery for advanced ovarian cancer. Gynecol Oncol Rep. 2021 Nov; 38:100870. View on PubMed
  19. Craig AD, Garcia E, Peters PN, Chen LM, Chapman JS. Primary treatment of advanced ovarian cancer: how does the 'real world' practice? Future Oncol. 2021 Dec; 17(34):4687-4696. View on PubMed
  20. Peters PN, Pierson WE, Chen LM, Westphalen AC, Chapman JS, Hsu IC. PET-detected asymptomatic recurrence is associated with improved survival in recurrent cervical cancer. Abdom Radiol (NY). 2021 01; 46(1):341-350. View on PubMed

Go to UCSF Profiles, powered by CTSI